Integrating methadone or buprenorphine treatment of opioid use disorder (OUD) into HIV care is a recommended strategy for achieving UNAIDS 90-90-90 targets, and associated with improved antiretroviral therapy [ART] uptake in observational studies and a single-site U.S. trial, but adoption of HIV clinic-based buprenorphine has been limited in many countries. We hypothesized that HIV-infected persons with OUD in Vietnam randomized to HIV clinic-based buprenorphine versus methadone would experience comparable 12-month uptake of ART.
We conducted a non-blinded, multi-center non-inferiority trial randomizing people with HIV and DSM-5 moderate-to-severe OUD to HIV clinic-based buprenorphine versus referral for methadone for treatment of OUD in 6 Vietnam HIV clinics. The primary outcome was medical record documentation of ART prescription. Secondary outcomes included retention on OUD treatment and positive urine drug screen (UDS) for opiates, assessed at baseline, 3, 6, 9, and 12 months. Generalized linear mixed models assessed buprenorphine versus methadone and change in outcomes over time in intention-to-treat analyses.
Participants (n=281) were randomized to receive buprenorphine (n=141) or methadone (n=140). At baseline, 96.8% of participants were male, 45.9% employed, with mean age 38.3 (SD 6.1) years and 7.4 (SD 5.7) years since HIV diagnosis. Mean CD4 count was 405 (SD 224). At baseline, 100% tested positive for heroin and 18.7% for methamphetamines. Retention in treatment at 12 months was 75.9% for buprenorphine and 82.1% for methadone and did not differ by treatment group (p=0.92). Heroin use at 12 months decreased to 46.8% for buprenorphine and 51.4% for methadone and did not differ by treatment assignment at 12 months (p=0.58). ART receipt increased from 68.0% to 73.8% for buprenorphine and 67.9% to 80.7% for methadone, and was higher for participants on methadone versus buprenorphine at 12 months (p=0.009).
Both buprenorphine and methadone improved ART receipt despite modest decreases in heroin use, comparable to those achieved in U.S. practice. Opioid agonist treatment can help achieve UNAIDS 90-90-90 goals for ART uptake.